Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus FKUI 2021 per tanggal 30 Juni 2021 (428 artikel)
Publikasi Scopus FKUI 2021 per tanggal 30 Juni 2021 (428 artikel)
Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study
2021
European Journal of Orthopaedic Surgery and Traumatology
31
2
265
273
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089486454&doi=10.1007%2fs00590-020-02765-5&partnerID=40&md5=617ce3dfaeed87e7c027f5f3006ebb43
Department of Orthopaedic and Traumatology, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine, Universitas Indonesia, CMU 2 Building 5th Floor, Jl. Diponegoro 71, Jakarta Pusat, Indonesia; Department Histology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia; Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jl. Salemba 6, Jakarta, Indonesia
Introduction: The current ‘gold-standard’ treatment of critical-sized bone defects (CSBDs) is autografts; however, they have drawbacks including lack of massive bone source donor site morbidity, incomplete remodeling, and the risk of infection. One potential treatment for treating CSBDs is bone marrow-derived mesenchymal stem cells (BM-MSCs). Previously, there were no studies regarding the use of human umbilical cord-mesenchymal stem cells (hUC-MSCs) for treating BDs. We aim to investigate the use of allogeneic hUC-MSCs for treating CSBDs. Method: We included subjects who were diagnosed with non-union fracture with CSBDs who agreed to undergo hUC-MSCs implantation. All patients were given allogeneic hUC-MSCs. All MSCs were obtained and cultured using the multiple-harvest explant method. Subjects were evaluated functionally using the Lower Extremity Functional Scale (LEFS) and radiologically by volume defect reduction. Result: A total of seven (3 male, 4 female) subjects were recruited for this study. The subjects age ranged from 14 to 62 years. All seven subjects had increased LEFS during the end of the follow-up period, indicating improved functional ability. The follow-up period ranged from 12 to 36 months. One subject had wound dehiscence and infection, and two subjects developed partial union. Conclusion: Umbilical cord mesenchymal stem cells are a potential new treatment for CSBDs. Additional studies with larger samples and control groups are required to further investigate the safety and efficacy of umbilical cord-derived mesenchymal stem cells for treating CSBDs. © 2020, Springer-Verlag France SAS, part of Springer Nature.
adolescent; adult; allotransplantation; Article; bone defect; clinical article; clinical outcome; critical sized bone defect; female; follow up; fracture nonunion; functional status; human; human cell; Lower Extremity Functional Scale; male; mesenchymal stem cell transplantation; middle aged; priority journal; surgical infection; time to treatment; umbilical cord mesenchymal stem cell; wound dehiscence; young adult
Springer-Verlag Italia s.r.l.
16338065
32804289
Article
Q2
681
7162